Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance

被引:33
作者
Jakobsen, CG
Bodtger, U
Poulsen, LK
Roggen, EL
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark
[2] Novozymes, Prot Screening, Bagsvaerd, Denmark
[3] Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark
关键词
affinity; allergen specific immunotherapy; allergy; Bet v 1; IgE; IgG1; IgG4; surface plasmon resonance;
D O I
10.1111/j.1365-2222.2005.02160.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Allergen-specific immunotherapy (SIT) is associated with increased levels of allergen-specific IgG in serum. However, it is not clear to what extent qualitative changes in the allergen binding capacity of IgG may be induced as well. Objective The purpose of this study was to investigate the influences of SIT on antibody affinity. Methods The binding affinity of purified serum IgG1, IgG4 and IgE to the major allergen in birch (Betula verrucosa) pollen, Bet v 1, was analysed by surface plasmon resonance. The antibodies were obtained from 10 birch pollen-allergic patients receiving SIT and from 10 patients with no SIT. Results The patients having received SIT have a significant higher titre of anti-Bet v 1 antibodies in their blood, but the affinity to Bet v 1 of allergen-specific IgE, IgG1 and IgG4 does not differ between the two groups. For IgG1 and IgG4, correlations between less allergic symptoms and affinity of the antibodies were observed both in the SIT group and to a smaller extent in the non-SIT group. Conclusion SIT has no effect on antibody affinity of allergen-specific IgE, IgG1 or IgG4. Allergic patients with high-affinity IgG1 and IgG4 antibodies report less symptoms than patients with low-affinity antibodies.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 38 条
[1]   Mechanisms of allergen-specific immunotherapy [J].
Akdis, CA ;
Blaser, K .
ALLERGY, 2000, 55 (06) :522-530
[2]   Increased frequency of intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis [J].
Aleksza, M ;
Irinyi, B ;
Lukács, A ;
Antal-Szalmás, P ;
Hunyadi, J ;
Szegedi, A .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (06) :1135-1141
[3]  
Balda BR, 1998, ALLERGY, V53, P740
[4]   Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus:: A randomized, double-blind, placebo-controlled trial in asthmatic patients [J].
Basomba, A ;
Tabar, AI ;
de Rojas, DHF ;
García, BE ;
Alamar, R ;
Olaguibel, JM ;
del Prado, JM ;
Martín, S ;
Rico, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (06) :943-948
[5]   Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: Differences from hydrocortisone-treated dendritic cells [J].
Bellinghausen, I ;
Brand, U ;
Steinbrink, K ;
Enk, AH ;
Knop, J ;
Saloga, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) :242-249
[6]   The kinetics of change in cytokine production by CD4+T cells during conventional allergen immunotherapy [J].
Benjaponpitak, S ;
Oro, A ;
Maguire, P ;
Marinkovich, V ;
DeKruyff, RH ;
Umetsu, DT .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (03) :468-475
[7]   The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study [J].
Bodtger, U ;
Poulsen, LK ;
Jacobi, HH ;
Malling, HJ .
ALLERGY, 2002, 57 (04) :297-305
[8]   4 RECOMBINANT ISOFORMS OF COR ALPHA-I, THE MAJOR ALLERGEN OF HAZEL POLLEN, SHOW DIFFERENT IGE-BINDING PROPERTIES [J].
BREITENEDER, H ;
FERREIRA, F ;
HOFFMANNSOMMERGRUBER, K ;
EBNER, C ;
BREITENBACH, M ;
RUMPOLD, H ;
KRAFT, D ;
SCHEINER, O .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 212 (02) :355-362
[9]  
Chowdhury I, 1999, ANN AGR ENV MED, V6, P91
[10]   Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever) [J].
Cooke, RA ;
Barnard, JH ;
Hebald, S ;
Stull, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1935, 62 (06) :733-U1